万邦德(002082) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 was ¥332,630,226.54, a decrease of 42.85% compared to ¥582,004,755.24 in the same period last year[3] - Net profit attributable to shareholders was ¥24,786,291.16, down 10.10% from ¥27,572,053.71 year-on-year[3] - The net profit excluding non-recurring gains and losses increased by 51.91% to ¥21,136,499.31 from ¥13,914,168.13 in the previous year[3] - Total operating revenue for Q1 2022 was CNY 332,630,226.54, a decrease from CNY 582,004,755.24 in the previous period[17] - Net profit for Q1 2022 was CNY 21,717,056.80, compared to CNY 27,131,157.80 in the same period last year[19] - Earnings attributable to the parent company for Q1 2022 were CNY 24,786,291.16, a decrease from CNY 27,572,053.71 in the previous year[19] - Comprehensive income for Q1 2022 was CNY 44,210,324.73, an increase from CNY 24,306,076.47 in the previous year[19] Cash Flow - The net cash flow from operating activities improved by 52.91%, reaching -¥86,915,507.07 compared to -¥184,585,297.73 in the same period last year[3] - The company reported a total cash flow from operating activities of CNY 4,218,398.34 for Q1 2022[19] - Cash inflow from operating activities totaled 419,489,821.15, down 31.2% from 610,759,549.83 in the prior period[21] - Cash outflow from operating activities was 506,405,328.22, a decrease of 36.4% compared to 795,344,847.56 in the previous period[21] - The net cash flow from investing activities was -62,692,040.49, a significant decline from 531,654,347.83 in the last period[22] - Cash inflow from investing activities was 9,103,070.12, a drop of 98.7% from 680,471,465.44 in the previous period[22] - Cash outflow from investing activities totaled 71,795,110.61, down 51.8% from 148,817,117.61 in the prior period[22] - The net cash flow from financing activities was -60,407,800.65, an improvement from -457,494,235.96 in the previous period[22] - Cash inflow from financing activities was 115,048,915.12, a decrease of 65.9% compared to 337,556,526.78 in the last period[22] - Cash outflow from financing activities was 175,456,715.77, down 77.9% from 795,050,762.74 in the previous period[22] - The ending cash and cash equivalents balance was 696,808,622.34, an increase from 459,266,203.64 in the prior period[22] Assets and Liabilities - Total assets decreased by 4.57% to ¥4,171,668,326.64 from ¥4,371,377,020.86 at the end of the previous year[3] - The company’s total liabilities increased to CNY 2.22 billion from CNY 2.15 billion, reflecting a rise of about 3.2%[15] - Total liabilities as of Q1 2022 amounted to CNY 1,390,802,992.05, down from CNY 1,626,694,346.84 in the previous period[16] - Total equity as of Q1 2022 was CNY 2,780,865,334.59, compared to CNY 2,744,682,674.02 in the previous period[16] - The company’s total equity attributable to shareholders increased by 1.11% to ¥2,627,246,483.33 from ¥2,598,357,643.63 at the end of the previous year[4] Operating Costs and Expenses - The company reported a significant reduction in operating costs, which fell by 57.61% to ¥167,154,617.63 from ¥394,280,743.62 year-on-year[8] - Total operating costs for Q1 2022 were CNY 311,988,803.46, down from CNY 564,433,824.80 in the previous period[17] - Research and development expenses decreased by 35.20% to ¥14,046,918.09 from ¥21,678,678.82 in the previous year[8] - Research and development expenses for Q1 2022 were CNY 14,046,918.09, down from CNY 21,678,678.82 in the previous year[17] Strategic Developments - The company has divested from aluminum processing businesses, which significantly impacted revenue comparisons with the previous year[4] - The company’s subsidiary successfully passed the FDA 510(k) review for its medical surgical masks and self-destructing syringes, enhancing its competitiveness in the international market[12] - The company plans to accelerate the market promotion of its isopropyl phenol injection, leveraging its production advantages in raw materials and formulations[11] Other Income - The company received government subsidies amounting to ¥1,187,312.01 during the quarter, contributing to a 959.36% increase in other income[8]